/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

M

Michael Pohl

University Hospitals of the Ruhr-University of Bochum(DE)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

115

Papers

5.5K

Citations

27

h-index

41

i10-index

Michael Pohl is an academic researcher from University Hospitals of the Ruhr-University of Bochum. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Gastric Cancer Management and Outcomes & Cancer Genomics and Diagnostics. The author has an h-index of 27, co-authored 98 publications.

ORCID: 0000-0002-9706-9471

Research Topics

Colorectal Cancer Treatments and Studies Gastric Cancer Management and Outcomes Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations Pancreatic and Hepatic Oncology Research

Papers by this author

works

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

2019 · The Lancet · 2,440 citations

https://doi.org/10.1016/s0140-6736(18)32557-1

Salah‐Eddin Al‐Batran Nils Homann Claudia Pauligk Thorsten Oliver Goetze

Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase <scp>II</scp> trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group

2021 · International Journal of Cancer · 97 citations

https://doi.org/10.1002/ijc.33696

Ralf‐Dieter Hofheinz S. Hegewisch-Becker Volker Kunzmann Peter Thuss‐Patience

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

2015 · European Journal of Cancer · 61 citations

https://doi.org/10.1016/j.ejca.2015.01.059

Sylvie Lorenzen Jorge Riera Knorrenschild Georg-Martin Haag Michael Pohl

Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer

2018 · Translational Oncology · 43 citations

https://doi.org/10.1016/j.tranon.2017.12.010

Susanne Klein‐Scory M. V. Maslova Michael Pohl Christina Eilert-Micus

Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo

2009 · Journal of Cancer Research and Clinical Oncology · 23 citations

https://doi.org/10.1007/s00432-009-0579-3

Michael Pohl Ingo Stricker A Schoeneck Karsten Schulmann

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

2021 · Genome Medicine · 14 citations

https://doi.org/10.1186/s13073-021-00926-7

Deepak Vangala Swetlana Ladigan Sven T. Liffers Soha Noseir

Research topics

topics

Colorectal Cancer Treatments and Studies

Gastric Cancer Management and Outcomes

Cancer Genomics and Diagnostics

Lung Cancer Treatments and Mutations

Pancreatic and Hepatic Oncology Research

Chat about Author

Papers

Chat

Click to start Chat